Xiangyu Medical Co.,Ltd (SHA:688626)
36.97
-1.07 (-2.81%)
Sep 11, 2026, 3:00 PM CST
Xiangyu Medical Co.,Ltd Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 781.87 | 767.75 | 743.53 | 744.81 | 488.53 | 523.5 |
Revenue Growth | 2.24% | 3.26% | -0.17% | 52.46% | -6.68% | 5.65% |
Gross Profit Gross Profit Growth | 513.48 | 501.56 | 490.92 | 501.46 | 318.44 | 353.92 |
Operating Income Operating Income Growth | 58.82 | 36.31 | 69.19 | 191.15 | 53.67 | 142.15 |
Net Income Net Income Growth | 82.42 | 78.16 | 102.94 | 227.14 | 125.47 | 201.9 |
Earnings Per Share EPS Growth | 0.54 | 0.51 | 0.66 | 1.44 | 0.79 | 1.35 |
EPS Growth | 2.00% | -22.73% | -54.17% | 82.28% | -41.48% | -17.68% |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
China China Growth | 751.95 |
Overseas Overseas Growth | 15.79 |
Total Total Growth | 767.75 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 899.35 | 1,024 | 743.18 | 825.98 | 1,363 | 1,478 |
Total Debt Total Debt Growth | 574.78 | 574.2 | 366.35 | 35.46 | 17.15 | - |
Net Cash (Debt) Net Cash Growth | 324.57 | 450.05 | 376.83 | 790.52 | 1,346 | 1,478 |
Net Cash Growth | 46.59% | 19.43% | -52.33% | -41.25% | -8.94% | 237.97% |
Net Cash Per Share Net Cash Per Share Growth | 2.13 | 2.94 | 2.42 | 5.01 | 8.47 | 9.88 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 180.56 | 189.82 | 178.59 | 227.91 | 186.7 | 165.88 |
Capital Expenditures CapEx Growth | -210.95 | -287.18 | -438.89 | -479.26 | -203.07 | -133.91 |
Free Cash Flow Free Cash Flow Growth | -30.39 | -97.37 | -260.3 | -251.35 | -16.37 | 31.97 |
Free Cash Flow Growth | - | - | - | - | - | -58.31% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 65.67% | 65.33% | 66.03% | 67.33% | 65.18% | 67.61% |
Operating Margin | 7.52% | 4.73% | 9.30% | 25.66% | 10.99% | 27.15% |
Pretax Margin | 10.07% | 9.69% | 14.42% | 32.76% | 27.22% | 42.54% |
Profit Margin | 10.54% | 10.18% | 13.84% | 30.50% | 25.68% | 38.57% |
FCF Margin | -3.89% | -12.68% | -35.01% | -33.75% | -3.35% | 6.11% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.180 | 0.180 | 0.240 | 0.530 | 0.240 | 0.380 |
Dividend Per Share Growth | -25.00% | -25.00% | -54.73% | 120.90% | -36.84% | 2.70% |
Dividend Yield | 0.44% | 0.30% | 0.83% | 1.02% | 0.78% | 0.70% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 68.44 | 120.81 | 44.43 | 36.87 | 40.08 | 45.11 |
Forward PE | 57.77 | 73.66 | 15.53 | 27.97 | 24.02 | 33.29 |
P/FCF Ratio | - | - | - | - | - | 284.86 |
PS Ratio | 7.38 | 12.30 | 6.15 | 11.24 | 10.29 | 17.40 |